Skip to main content

Table 2 Results of univariate analysis for OS, DFS, pelvic control and distant control

From: Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy

Variables OS DFS Pelvic control Distant control
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age (< 65 vs ≥65) 2.01 (1.29–3.13) 0.002 1.38 (0.92–2.07) 0.124 0.99 (0.51–1.90) 0.968 1.20 (0.69–2.11) 0.516
Histology (SCC vs AC) 2.01 (1.22–3.31) 0.006 2.21 (1.49–3.25) < 0.001 2.33 (1.36–3.99) 0.002 1.96 (1.15–3.32) 0.013
FIGO stage (I, II and III-IVA) 2.24 (1.65–3.06) < 0.001 1.96 (1.52–2.52) < 0.001 1.87 (1.31–2.69) 0.001 1.76 (1.26–2.45) 0.001
Tumour size (< 4 cm vs ≥4 cm) 2.74 (1.80–4.17) < 0.001 2.43 (1.74–3.39) < 0.001 2.60 (1.59–4.26) < 0.001 2.20 (1.44–3.36) < 0.001
Para-aortic MLNs (No vs Yes) 6.09 (4.05–9.15) < 0.001 5.10 (3.55–7.34) < 0.001 6.66 (4.18–10.60) < 0.001 3.05 (1.77–5.26) < 0.001
Pelvic MLNs (No vs Yes) 3.21 (2.28–4.50) < 0.001 2.90 (2.20–3.84) < 0.001 3.23 (2.16–4.82) < 0.001 2.63 (1.82–3.79) < 0.001
Common iliac MLNs (No vs Yes) 5.68 (3.83–8.43) < 0.001 4.17 (2.91–5.98) < 0.001 3.55 (2.12–5.93) < 0.001 4.20 (2.64–6.70) < 0.001
Number of pelvic MLNs (continuous) 1.29 (1.24–1.35) < 0.001 1.27 (1.22–1.32) < 0.001 1.25 (1.19–1.32) < 0.001 1.22 (1.15–1.28) < 0.001
Concurrent chemotherapy (No vs Yes) 0.67 (0.45–0.99) 0.046 0.71 (0.51–0.99) 0.044 0.72 (0.44–1.16) 0.178 0.83 (0.53–1.32) 0.433
  1. AC adenocarcinoma, CI confidence interval, FIGO the International Federation of Gynaecology and Obstetrics, HR hazard ratio, MLNs metastatic lymph nodes, SCC squamous cell carcinoma